UA113000C2 - Спосіб отримання вакцини, яка містить щонайменше два антигени, які здатні адсорбуватися на оксигідроксиді алюмінію - Google Patents

Спосіб отримання вакцини, яка містить щонайменше два антигени, які здатні адсорбуватися на оксигідроксиді алюмінію

Info

Publication number
UA113000C2
UA113000C2 UAA201409180A UAA201409180A UA113000C2 UA 113000 C2 UA113000 C2 UA 113000C2 UA A201409180 A UAA201409180 A UA A201409180A UA A201409180 A UAA201409180 A UA A201409180A UA 113000 C2 UA113000 C2 UA 113000C2
Authority
UA
Ukraine
Prior art keywords
aloon
antigen
hepatitis
aluminum
vaccine
Prior art date
Application number
UAA201409180A
Other languages
English (en)
Inventor
Ландрі Берто
Ізабелль Шакорнак
Ален Франсон
Жан-Франсуа О
Граф Сандрін Лентш
Original Assignee
Санофі Пастер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофі Пастер filed Critical Санофі Пастер
Publication of UA113000C2 publication Critical patent/UA113000C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Винахід належить до способу отримання вакцинної композиції, яка містить щонайменше оксигідроксид алюмінію (АlOОН) і щонайменше поверхневий антиген гепатиту В, і антиген Haemophilus influenzae типу b. Згідно з винаходом поверхневий антиген гепатиту В зберігається адсорбованим на АlOОН, тоді як антиген Hib зберігається неадсорбованим. З цією метою: поверхневий антиген гепатиту В адсорбують на АlOОН для отримання комплексу АlOОН/HBsAg, потім вказаний комплекс АlOОН /HBsAg змішують із антигеном Hib у присутності катіонних амінокислот у концентрації щонайменше 100 мг/л і фосфатних іонів у концентрації від 35 до 45 ммоль/л.
UAA201409180A 2012-01-17 2013-01-17 Спосіб отримання вакцини, яка містить щонайменше два антигени, які здатні адсорбуватися на оксигідроксиді алюмінію UA113000C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1250464A FR2985663B1 (fr) 2012-01-17 2012-01-17 Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
PCT/FR2013/050106 WO2013107988A1 (fr) 2012-01-17 2013-01-17 Procédé de formulation d'un vaccin contenant au moins deux antigènes susceptibles de s'adsorber sur de l'oxyhydroxyde d'aluminium

Publications (1)

Publication Number Publication Date
UA113000C2 true UA113000C2 (uk) 2016-11-25

Family

ID=47714410

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201409180A UA113000C2 (uk) 2012-01-17 2013-01-17 Спосіб отримання вакцини, яка містить щонайменше два антигени, які здатні адсорбуватися на оксигідроксиді алюмінію

Country Status (34)

Country Link
US (1) US9358294B2 (uk)
EP (1) EP2804628B1 (uk)
JP (2) JP6199310B2 (uk)
KR (1) KR102019848B1 (uk)
CN (1) CN104039348B (uk)
AP (1) AP2014007848A0 (uk)
AR (1) AR089737A1 (uk)
AU (1) AU2013210927B2 (uk)
BR (1) BR112014017416B1 (uk)
CA (1) CA2861304C (uk)
CR (1) CR20140356A (uk)
CY (1) CY1119206T1 (uk)
DK (1) DK2804628T3 (uk)
EA (1) EA026058B1 (uk)
ES (1) ES2625011T3 (uk)
FR (1) FR2985663B1 (uk)
GE (1) GEP201706642B (uk)
GT (1) GT201400120A (uk)
HK (1) HK1204293A1 (uk)
HR (1) HRP20170692T1 (uk)
HU (1) HUE032539T2 (uk)
IL (1) IL233643A (uk)
LT (1) LT2804628T (uk)
MX (1) MX349411B (uk)
NZ (1) NZ627345A (uk)
PE (1) PE20141515A1 (uk)
PH (1) PH12014501546A1 (uk)
PL (1) PL2804628T3 (uk)
PT (1) PT2804628T (uk)
RS (1) RS55962B1 (uk)
SI (1) SI2804628T1 (uk)
UA (1) UA113000C2 (uk)
WO (1) WO2013107988A1 (uk)
ZA (1) ZA201405431B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
TW202308684A (zh) 2021-04-20 2023-03-01 日商Ｋｍ生物醫藥股份有限公司 六合一液狀疫苗組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835663B1 (en) * 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising Hepatitis B surface antigen and other antigens
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
CA2303105A1 (en) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
EP1414433B1 (en) 2001-08-07 2006-04-12 Laboratoires SMB SA Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
FR2828406B1 (fr) 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
GB0610140D0 (en) * 2006-05-22 2006-06-28 Insense Ltd Protein stability
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion

Also Published As

Publication number Publication date
CY1119206T1 (el) 2018-02-14
SI2804628T1 (sl) 2017-06-30
CA2861304A1 (fr) 2013-07-25
BR112014017416A8 (pt) 2017-07-04
AP2014007848A0 (en) 2014-08-31
ES2625011T3 (es) 2017-07-18
JP6199310B2 (ja) 2017-09-20
IL233643A0 (en) 2014-08-31
CN104039348A (zh) 2014-09-10
CA2861304C (fr) 2021-05-25
HK1204293A1 (en) 2015-11-13
CR20140356A (es) 2014-08-28
NZ627345A (en) 2016-07-29
AU2013210927A1 (en) 2014-08-28
JP2017203043A (ja) 2017-11-16
JP6356886B2 (ja) 2018-07-11
US9358294B2 (en) 2016-06-07
PH12014501546B1 (en) 2014-10-08
BR112014017416A2 (pt) 2021-05-25
LT2804628T (lt) 2017-05-25
PE20141515A1 (es) 2014-11-04
CN104039348B (zh) 2016-05-11
EA026058B1 (ru) 2017-02-28
FR2985663B1 (fr) 2015-03-27
MX2014007850A (es) 2014-08-21
WO2013107988A1 (fr) 2013-07-25
MX349411B (es) 2017-07-27
EA201491387A1 (ru) 2014-12-30
KR20140119109A (ko) 2014-10-08
HRP20170692T1 (hr) 2017-07-14
KR102019848B1 (ko) 2019-09-09
HUE032539T2 (hu) 2017-10-30
BR112014017416B1 (pt) 2022-08-16
AU2013210927B2 (en) 2017-02-23
US20140370049A1 (en) 2014-12-18
PL2804628T3 (pl) 2017-08-31
PH12014501546A1 (en) 2014-10-08
EP2804628B1 (fr) 2017-03-01
IL233643A (en) 2017-04-30
GEP201706642B (en) 2017-03-27
ZA201405431B (en) 2015-12-23
GT201400120A (es) 2015-09-17
PT2804628T (pt) 2017-04-21
DK2804628T3 (en) 2017-05-22
AR089737A1 (es) 2014-09-10
JP2015504085A (ja) 2015-02-05
RS55962B1 (sr) 2017-09-29
FR2985663A1 (fr) 2013-07-19
EP2804628A1 (fr) 2014-11-26

Similar Documents

Publication Publication Date Title
GEP20237513B (en) Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
MY183415A (en) Anti-c5 antibodies and methods of use
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
WO2013048883A3 (en) Anti-erbb3 antibodies and uses thereof
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
MX343914B (es) Adsorcion de inmunopotenciadores en sales metalicas insolubles.
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
EA201300127A1 (ru) Комбинированная фармацевтическая композиция и способ лечения головокружения различного генеза, кинетоза и вегетососудистой дистонии
MX356454B (es) Una formulacion enzimatica liquida y un proceso para su preparacion.
UA113000C2 (uk) Спосіб отримання вакцини, яка містить щонайменше два антигени, які здатні адсорбуватися на оксигідроксиді алюмінію
MX367150B (es) Partículas de rotavirus con proteínas de superficie quiméricas.
TN2013000342A1 (en) Sildenafil-free base-containing film preparation and method for producing same
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
GB2496801A (en) A method of treating alzheimer's disease
WO2015006728A3 (en) Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
UA112755C2 (uk) Метод лікування синдрому дефіциту уваги і гіперактивності
EA201291437A1 (ru) Концентрация вакцинных антигенов без лиофилизации
WO2010132047A8 (en) Guanosine/gmp gels and uses thereof
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2010040136A3 (en) Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies
IN2015DN02730A (uk)
RU2012134847A (ru) Способ определения стадии дефицита железа
GB201015223D0 (en) Vaccines